Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages

• Main Authors: Bradley K. Ackerson (Author), Katia J. Bruxvoort (Author), Lei Qian (Author), Lina S. Sy (Author), Sijia Qiu (Author), Julia E. Tubert (Author), Gina S. Lee (Author), Jennifer H. Ku (Author), Ana Florea (Author), Yi Luo (Author), Radha Bathala (Author), Julie Stern (Author), Soon K. Choi (Author), Harpreet S. Takhar (Author), Michael Aragones (Author), Morgan A. Marks (Author), Evan J. Anderson (Author), Cindy Ke Zhou (Author), Tianyu Sun (Author), Carla A. Talarico (Author), Hung Fu Tseng (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTEmerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against circulating sublineages is important to inform the potential nee...